MMN, or multifocal motor neuropathy, is a rare autoimmune condition that causes progressive weakness in the hands, arms, and sometimes legs. Unlike many nerve disorders, it affects only motor nerves, the ones that control muscle movement, while leaving sensation intact. The weakness tends to be asymmetric, meaning it can affect one hand or arm more than the other, and it typically starts in the upper limbs before involving the lower ones.
How MMN Affects the Nerves
In a healthy nervous system, a fatty coating called myelin wraps around nerve fibers and helps electrical signals travel quickly from the brain to the muscles. Along each nerve fiber, there are small gaps in this coating where the signal essentially “jumps” from one point to the next. A specific molecule called GM1 sits at these gaps and in the surrounding myelin, helping to anchor the ion channels that keep electrical signals moving at the right speed.
In MMN, the immune system produces antibodies that target GM1. When these antibodies bind to the gaps and surrounding areas, they trigger an inflammatory cascade that damages the nerve’s protective coating and disrupts the ion channels needed for signal transmission. The result is a “conduction block,” where the electrical signal simply stops partway along the nerve and never reaches the muscle. GM1 is far more abundant in motor nerves than in sensory nerves, which explains why people with MMN lose strength but can still feel touch, temperature, and pain normally.
What the Weakness Feels Like
MMN weakness follows a distinctive pattern. Rather than affecting an entire limb evenly, it strikes along the path of individual named nerves. You might notice that your grip weakens in one hand while the other feels fine, or that specific finger movements become difficult while the rest of your hand works normally. The progression is usually slow or stepwise, meaning you may go weeks or months without change, then notice a new area of weakness.
Most people with MMN do not experience numbness, tingling, or pain. About 20% report mild sensory changes in the feet or lower legs, but objective sensory loss on examination is absent. Muscle wasting can develop over time, particularly in the hands and forearms, though this tends to lag behind the weakness itself.
Why It Can Be Mistaken for ALS
Because MMN causes pure motor weakness without sensory symptoms, it can initially look like amyotrophic lateral sclerosis (ALS). This distinction matters enormously: ALS is a progressive, fatal neurodegenerative disease, while MMN is treatable. The key differences are that MMN does not produce upper motor neuron signs like exaggerated reflexes, spasticity, or speech and swallowing difficulties. MMN weakness also follows the territory of specific peripheral nerves rather than affecting entire muscle groups supplied by the spinal cord. Getting the diagnosis right can spare patients from an incorrect ALS diagnosis and connect them with effective therapy.
How MMN Is Diagnosed
Diagnosis requires two main pieces of evidence. First, a neurologist needs to confirm weakness without sensory loss in the territory of at least two separate named nerves. Second, nerve conduction studies must show conduction blocks in at least two motor nerves, and these blocks must occur in locations that aren’t common compression points (like the wrist or elbow, where nerves can get pinched for other reasons).
A blood test for anti-GM1 antibodies supports the diagnosis but isn’t definitive on its own. About 48% of MMN patients test positive, and the test is highly specific at 93%, meaning a positive result strongly suggests MMN rather than another condition. However, a negative result doesn’t rule it out, since roughly half of confirmed MMN patients don’t have detectable antibodies.
Treatment With Immunoglobulin Therapy
The standard treatment is intravenous immunoglobulin, commonly called IVIG. This involves receiving purified antibodies from donated blood plasma through an IV infusion. The initial course typically runs over five consecutive days, and most patients then need maintenance infusions every three to eight weeks to sustain improvement. The treatment is dose and frequency dependent, meaning your neurologist will adjust the schedule based on how you respond.
IVIG works in part by reducing the inflammatory damage that anti-GM1 antibodies cause at nerve junctions. Most people notice improved strength within the first few weeks of treatment. However, IVIG does not cure MMN. It manages the condition, and most patients require ongoing infusions for years or indefinitely. Steroids and plasma exchange, which help in other autoimmune nerve conditions, are not effective for MMN and can actually worsen symptoms.
Long-Term Outlook
MMN is a chronic condition, but it is not life-threatening. A population-based study of patients with a median disease duration of 24 years found that most maintained the ability to walk and live independently, though measurable impairments accumulated over time. Compared to healthy individuals, long-term MMN patients showed grip strength reduced by 56%, overall limb strength reduced by 29%, and walking speed slowed by about 13%. The most significant long-term challenges involve dexterity, particularly fine hand movements, and ankle stability. One patient in the study had lost the ability to walk due to ankle weakness, but this was an outlier.
One of the most important findings from long-term research is that delays in starting treatment lead to worse outcomes regardless of how long someone has had the disease. In other words, the sooner IVIG therapy begins after symptoms appear, the better the long-term prognosis. Early treatment helps preserve nerve function before irreversible damage to the underlying nerve fibers sets in, which is the main driver of permanent weakness and muscle wasting.